Abstract
s S59 those patients with size (defined as > 30% height/weight difference) or gender mismatch to a control group without mismatch. Results: Pediatric donor hearts in all groups had similar 3-year survival, freedom from CAV and NF-MACE to those adult recipients receiving adult donor hearts (See table). 1-year freedom from acute cellular and antibodymediated rejection were also similar. Gender mismatch did not appear to be significant risk factor (data not shown). Size mismatch did not adversely affect outcome among the study groups (see table). Conclusion: The use of pediatric donor hearts, even pre-puberty donor hearts, in appropriately selected adults appear to be viable with acceptable outcomes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
